BEIJING, China – September 22, 2025 – MediumBank (Shanghai MediumBank Biotechnology Co., Ltd.) successfully hosted the "Unlocking Upstream Potential, Ensuring Supply Security" Upstream Bioprocessing Technical Seminar in Beijing. The event gathered industry peers to explore forefront developments in upstream bioprocessing and share practical insights.
The seminar featured a series of expert presentations covering key industry topics, including tumor immunotherapy research, advancements in biological products for pets, and the application of suspension cell technology in animal vaccine development. MediumBank representatives also delivered in-depth technical reports, focusing on strategies for ensuring stable supply and quality in cell culture media, as well as methodologies for optimizing media formulation to enhance monoclonal antibody production processes.
An interactive session facilitated active discussions and knowledge exchange among participants.
The seminar also marked a significant milestone with the formalization of a strategic partnership between Joinn Biologics and MediumBank. Dr. Geng Shusheng, Co-founder and General Manager of Joinn Biologics, and Mr. Wang Yantao, Founder and CEO of MediumBank, jointly signed the cooperation agreement, signifying a strengthened collaboration in the bioprocessing field.
This event highlighted the innovative potential within the North China biopharmaceutical sector. MediumBank remains dedicated to advancing its vision of "Making Bioprocessing Simpler and More Efficient" and looks forward to fostering further collaboration to support the industry's growth.
We anticipate future opportunities for continued dialogue and shared progress.
